COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00137410
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : June 10, 2008
Information provided by:

Brief Summary:
This is a phase III, multicentre, randomized, double blind, parallel-group, pilot study designed to compare a long term (12 weeks) versus a short term (2 weeks) treatment with celecoxib 200 mg/die in treatment and prevention of new flare in patients with osteoarthritis of the knee.

Condition or disease Intervention/treatment Phase
Osteoarthritis,Knee Drug: Celebrex Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Protocol For A Multicentre, Double Blind, Parallel Group Pilot Study To Compare Celecoxib Long Term Vs Celecoxib Short Term Therapy In Treatment And Prevention Of New Flare In Patients With Osteoarthritis Of The Knee
Study Start Date : November 2002
Actual Primary Completion Date : March 2006
Actual Study Completion Date : March 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
Drug Information available for: Celecoxib

Primary Outcome Measures :
  1. Time elapsing between the last drug administration and a new flare, if any, occurring within a 12 months FU and proportion pts with a new flare

Secondary Outcome Measures :
  1. Flare intensity WOMAC OA index Psycho-affective Index Pt's assessment of OA pain (VAS) Pt's & Physician's global assessment disease severity Incidence of total AEs Incidence of GI AEs: Incidence of changes in: hematology, renal function, liver function

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosis of OA of the knee according to the ACR Classification Criteria for osteoarthritis;
  • patients in flare

Exclusion Criteria:

  • any concomitant inflammatory rheumatic condition which may interfere with the assessment of OA
  • clinical or radiological evidence of chondrocalcinosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00137410

Layout table for location information
Pfizer Investigational Site
Rutigliano, BA, Italy, 70018
Pfizer Investigational Site
Arenzano (GE), Italy, 16011
Pfizer Investigational Site
Cagliari - Monserrato, Italy
Pfizer Investigational Site
Foggia, Italy, 71100
Pfizer Investigational Site
Genova, Italy, 16100
Pfizer Investigational Site
Genova, Italy, 16132
Pfizer Investigational Site
Jesi ( AN), Italy, 60035
Pfizer Investigational Site
Milano, Italy, 20122
Pfizer Investigational Site
Milano, Italy, 20157
Pfizer Investigational Site
Padova, Italy, 35100
Pfizer Investigational Site
Palermo, Italy, 90146
Pfizer Investigational Site
Pavia, Italy, 27100
Pfizer Investigational Site
Potenza, Italy, 85100
Pfizer Investigational Site
Roma, Italy, 00149
Pfizer Investigational Site
Siena, Italy, 53100
Pfizer Investigational Site
Venezia, Italy, 30122
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Directorm Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00137410    
Other Study ID Numbers: 635-IFL-0508-015
First Posted: August 29, 2005    Key Record Dates
Last Update Posted: June 10, 2008
Last Verified: July 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis, Knee
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action